SCHEMBL25329148

SCHEMBL25329148

CS(=O)(=O)OCCC(F)(F)CCOc1ccc(C2CCN(c3ccc(C#N)c(C(F)(F)F)c3)CC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AR P10275 10/20 0.44
SCN9A Q15858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25928951 0.90 AR (0.40) ARSCN9A
SCHEMBL25328182 0.87 AR (0.42) AR
SCHEMBL31131388 0.87 AR (0.40) ARSCN9A
SCHEMBL25936331 0.86 AR (0.44) ARSCN9A
SCHEMBL25936546 0.86 AR (0.44) ARSCN9A
SCHEMBL31476797 0.82 AR (0.42) AR
SCHEMBL25328831 0.81 AR (0.44) AR
SCHEMBL25329434 0.81 AR (0.42) AR
SCHEMBL25329956 0.81 AR (0.42) ARSCN9A
SCHEMBL31131387 0.81 AR (0.42) AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4466260-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER Astrazeneca AB (SE) 2024-11-27 EP disclosed
WO-2023139199-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2023-07-27 WO disclosed